Human immunodeficiency virus-1 (HIV-1) infection affects the striatum, resulting in gliosis and neuronal losses. To determine whether HIV-1 proteins induce striatal neurotoxicity through an apoptotic mechanism, mouse striatal neurons isolated on embryonic day 15 and the effects of HIV-1 Tat 1-72 and gp120 on survival were assessed in vitro. Mitochondrial release of cytochrome c, caspase-3 activation, and neuron survival, as well as an alternative apoptotic pathway involving endonuclease G (endo G), were assessed at 4 h, 24 h, 48 h, and/or 72 h using enzyme assays and immunoblotting. Both HIV-1 Tat and gp120 significantly increased caspase-3 activation in a concentration-dependent manner in striatal neurons at 4 h following continuous exposure in vitro. Tat 1-72 and gp120 caused significant neuronal losses at 48 h and/or 72 h. Tat 1-72 increased cytochrome c release, and caspase-3 and endo G activation at 4 h, 24 h, and/or 72 h. By contrast, gp120 increased caspase-3 activation, but failed to increase cytochrome c or endo G levels in the cytoplasm at 4 h, 24 h, and/or 72 h. The cell permeant caspase inhibitor Z-DEVD-FMK significantly attenuated gp120-induced, but not Tat 1-72 -induced, neuronal death, suggesting that gp120 acts in large part through the activation of caspase(s), whereas Tat 1-72 -induced neurotoxicity was accompanied by activating an alternative pathway involving endo G. Thus, although Tat 1-72 and gp120 induced significant neurotoxicity, the nature of the apoptotic events preceding death differed. Collectively, our findings suggest that HIV-1 proteins are intrinsically toxic to striatal neurons and the pathogenesis is mediated through separate actions involving both caspase-3 and endo G. Journal of NeuroVirology (2004) 10, 141-151.
Introduction
Human immunodeficiency virus-1 (HIV-1) dementia is a neurodegenerative syndrome characterized by cognitive decline, personality change, and motor deficits in humans infected with HIV-1 (McArthur et al, 1993; Lipton and Gendelman, 1995) . HIV encephalitis (HIVE) often accompanies HIV dementia and is characterized by prominent microglial activation, neuronal losses, dendritic pruning, and decreased density of synapses (Masliah et al, 1996 ; IN Singh et al Lipton, 1997) . Apoptotic changes are seen with HIVE in both neurons and non-neuronal cells (Ramirez et al, 2001; Bonavia et al, 2001; Corasaniti et al, 2001; Adle-Biassette et al, 1995; Gelbard et al, 1995; Petito and Roberts, 1995; Shi et al, 1996; Kaul et al, 2001; Shi et al, 1998; Park et al, 2001) . HIV-1 is neurotoxic by inducing inflammation and through the direct release of toxic viral proteins such as Nef, Vpr, gp120, and Tat (Haughey et al, 2001; Brenneman et al, 1988; Dreyer et al, 1990; Adamson et al, 1996; New et al, 1997; Kruman et al, 1998; Yeung et al, 1998; Huang and Bond, 2000; Trillo-Pazos et al, 2000; Nath, 2002) . The neurotoxicity of gp120 has been demonstrated both in primary human neuronal cultures (Lannuzel et al, 1997; Yeung et al, 1995) and in transgenic mice (Toggas et al, 1994) . Gp120 is thought to be intrinsically neurotoxic through an apoptotic mechanism (Barillari et al, 1993; Albini et al, 1996a Albini et al, , 1996b Bagetta et al, 1996b; Hesselgesser et al, 1998; Marzo et al, 1998; Meucci et al, 1998; Zheng et al, 1999) and may also act via inflammatory cytokines (Bagetta et al, 1996a (Bagetta et al, , 1999 Lipton, 1997) .
HIV-1 Tat protein is not only an intracellular transcriptional activator, but is also secreted by infected cells and is capable of acting as a protocytokine. HIV-1 Tat can bind to and activate specific tyrosine kinase receptors, including the Flk-1/kinase insert domain (Flk-1/KDR) receptor for vascular endothelial growth factor (VEGF) and several classes of integrins (Albini et al, 1996a (Albini et al, , 1996b Barillari et al, 1993; Vogel et al, 1993) . HIV-1 Tat can trigger apoptosis in PC-12 neuronal cells through the induction of tumor necrosis factor-α release (New et al, 1998; Shi et al, 1998) . Tat is important in the pathogenesis of Kaposi's sarcoma and in the neuroinflammatory changes seen in patients with HIV dementia (Deregibus et al, 2002; Kaaya et al, 1996) . Apoptosis is often accompanied by the activation of caspases (Creagh and Martin, 2001; Schimmer et al, 2001; Stennicke and Salvesen, 2000) . Caspase-3 is a member of the CED-3 subfamily of caspases that is activated in several neurodegenerative disorders (Namura et al, 1998; Hartmann et al, 2000; Su et al, 2000) . Active caspase-3 has been detected by Western blot in human fetal neural cultures exposed to gp120 (Zheng et al, 1999) ; however, the specific cell population undergoing caspase activation was not identified. Postmortem studies on the brains of pediatric patients with HIV dementia showed increased procaspase-3 immunoreactivity in neurons (James et al, 1999) .
The basal ganglia are especially vulnerable to HIV infection (Berger and Nath et al, 2001) and this may result from unique phenotypic characteristics of striatal neurons compared to other neuron types. For example, striatal neurons are quite susceptible to α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor-mediated excitotoxic stimuli, but far less sensitive to N-methyl-D-aspartate (NMDA)-induced excitotoxicity Singh et al, 2003) . The basal ganglia are also a principal target for drug abuse and may be preferentially susceptible to interactions between HIV and drug abuse Nath, 2002) . For this reason, we examined the mechanisms underlying Tat and gp120 toxicity in striatal neurons and found that Tat 1−72 and gp120 induced apoptotic cell death in mouse striatal neurons.
Results
We first studied the concentration-dependence of HIV-1 Tat and gp120-induced activation of caspase-3 in striatal neurons at 4 h following continuous exposure in vitro. As shown in Figure 1 , both HIV-1 Tat and gp120 caused significant increases in caspase-3 activation in a concentration-dependent manner (P < .0001 versus untreated cultures) at 4 h following continuous exposure in vitro. The optimum concentration of HIV-1 Tat used being 100 nM whereas the optimum concentration of gp120 used being 500 pM for the measurement of neuronal viability and other biochemical studies described in this paper (Figure 1 ).
When Tat 1−72 and gp120 toxicity were assessed by time-lapse photomicrography in primary cultures derived from embryonic mouse striatum, both viral proteins were found to be intrinsically toxic to striatal neurons (Figure 2 ). High rates of death were seen 72 h after exposure to either Tat 1−72 (100 nM) ( Figure 2B ) or gp120 (500 pM) ( Figure 2D ). Although some background neuronal death is normally present in striatal neuron cultures at 7 to 10 days in vitro, increased rates of cytotoxicity were clearly evident following exposure to Tat or gp120 (see Figure 2A , B). To assess the extent and time course of viral protein-induced neuronal losses, the effects of Tat 1−72 and gp120 on neuronal death were quantified before and at 24-h intervals following continuous exposure to viral proteins ( Figure 3 ). The findings showed that gp120 caused rapid neuronal losses, with significant cytotoxicity occurring at 48 h, whereas Tat 1−72 caused significant toxicity after 72 h (Figure 3 ) ( * P < .05 versus controls treated with medium-vehicle alone).
Because Tat and gp120 toxicity has been associated with activation of caspases and apoptosis in astrocytes and neurons in other brain regions (Kruman et al, 1998; Su et al 2000; Garden et al, 2002; Haughey and Mattson, 2002) , we examined the effect of the cell-permeant pan-caspase inhibitor Z-DEVD-FMK on rates of Tat and gp120 toxicity in striatal neurons. Tat-induced neuronal death was unaffected in cultures coincubated with DEVD-FMK (30 μM) ( Figure 2C ), whereas pretreatment with DEVD-FMK protected neurons exposed to 500 pM gp120 ( Figure 2E ). The rate of neuronal death in DEVD-FMK-treated cultures did not differ significantly from controls treated with medium alone. Incubation with Z-DEVD-FMK (30 μM) significantly attenuated gp120-induced neuronal death ( Figure 3B ) ( # P < .01 versus gp120 treatment alone), but not Tat 1−72 -induced neuronal death ( Figure 3A ). These results suggested that gp120-induced neurotoxicity is mediated by caspase-3, whereas Tat 1−72 is neurotoxic through an alternative pathway independent of caspase-3.
To validate the time-lapse studies, striatal neuron death was assessed by colocalized immunofluorescent reactivity for the neuronal nuclear marker (NeuN) in dying cells that cannot exclude ethidium monoazide (EMA) at 24 h (Table 1, Figure 4 ). The inability to exclude EMA precedes overt pathological changes in neuronal morphology that accompany cell death. Cell cultures were exposed to EMA and assayed at 24 h following Tat or gp120 exposure. Moreover, it was anticipated that the proportion of dying neurons labeled by EMA would be less than that counted by repeated measures, because cells are incubated in EMA for a relatively short duration (30 min) and our experience from time-lapse studies is striatal neurons undergo death quite rapidly (<24 h). (100 nM) 1.00 ± .38 HIV-1 Tat 1−72 (100 nM) + DEVD (50 μM)
IN Singh et al
1.17 ± .24 HIV-1 gp120 (500 pM)
1.71 ± .31 * HIV-1 gp120 (500 pM) + DEVD (50 μM) 0.60 ± .33
Note. gp120 treatment caused significant neuronal losses at 24 h that could be significantly attenuated by pretreating cultures with the caspase inhibitor, Z-DEVD-FMK (DEVD). a Striatal neurons were continuously exposed to HIV-1 proteins and/or the soluble caspase inhibitor Z-DEVD-FMK (DEVD) and assayed at 24 h in vitro. b Neuronal viability was assessed by determining the proportion of neuronal nuclear (NeuN) immunoreactive neurons that failed to exclude ethidium monoazide (EMA) following 30 min incubation in EMA (see Figure 4) ; percentage nonviable neurons = (EMA and NeuN-positive neurons)/(total NeuN-positive neurons) × 100. * P < .05 versus vehicle-treated control or gp120-treated cultures.
In addition, to similarly assess the role of caspase-3 in Tat-and gp120-induced neuronal death, viral protein toxicity was assessed in the presence or absence of the pan-caspase inhibitor Z-DEVD-FMK (50 μM).
The results indicated significant gp120-induced neuronal losses at 24 h that were significantly attenuated by cotreating neurons with Z-DEVD-FMK (Table 1 , Figure 4B , C). In contrast, Tat 1−72 did not increase the proportion of EMA-positive NeuN-identified neurons at 24 h (Table 1) , which agreed with findings that Tat toxicity progresses more slowly than gp120-induced neuronal losses (Figure 3 ). To assess the extent and time course of viral protein-induced caspase-3 activation, the effects of Tat 1−72 and gp120 on caspase-3 activation were examined at 4 h, 24 h, and 72 h ( Figure 5 ). Caspase-3 was significantly elevated following Tat 1−72 or gp120 exposure at 4 h, 24 h, and 72 h. At 72 h, caspase-3 activity was significantly greater with Tat treatment than gp120 treatment ( Figure 5) ; however, at this time fewer viable neurons remain following gp120 treatment. Interestingly, despite findings that Z-DEVD-FMK failed to inhibit Tat-induced striatal neuron death ( Figure 3A) , Tat nevertheless caused significant increases in caspase-3 activity at 4 h, 24 h, and 72 h ( Figure 5 ). Lastly, to assure that our assay was specifically assessing caspase-3, Ac-DEVD-CHO, a highly selective (but cell-impermeant) caspase-3 inhibitor blocked caspase-3 activity when added to the cell lysates 30 min before incubation with caspase-3 substrate (Ac-DEVD-AMC; data not shown).
A key event in the mitochondrial-mediated pathway for caspase-3 activation is the release of cytochrome c into the cytoplasm (Kluck et al, 1997) . Increases in cytoplasmic levels of cytochrome c following HIV-1 Tat 1−72 and gp120 exposure were investigated in striatal neurons at 4 h and 72 h (Figure 6 ). (EMA) in striatal neuron cultures at 24 h following exposure to medium alone (A), gp120 (500 pM) with or without Z-DEVD-FMK (DEVD) (50 μM) (B, C), or DEVD alone (50 μM) (D). Cell cultures were incubated with DEVD for 4 h prior to exposure to gp120. gp120 treatment increased the proportion of dying neurons and the toxicity was prevented by coadministering DEVD (see Table 1 ). Viable NeuN immunofluorescence neurons (arrowheads) appear green and exclude EMA (red fluorescence) from their nuclei. Nonviable neurons (arrows) fail to exclude EMA (red) Tat (100 nM) was also assayed but showed no effect at 24 h (see Table 1 ). The large photomicrographs (right side) are composite images of NeuN reactivity (upper left insets) and EMA (lower left insets); scale bar = 20 μm.
As shown in Figure 6A -C, Tat 1−72 (100 nM), but not gp120 (500 pM), significantly increased levels of cytochrome c in the cytoplasm ( * P < .05 versus vehicle-treated control cultures; # P < .05 versus Tat 1−72 -treated neurons). Tat-induced increases in cytoplasmic levels coincided with declines in mitochondrial levels as expected and β-actin levels in the cytoplasm did not differ among treatments (data not shown). Although gp120 did not increase cytosolic levels of cytochrome c at 4 h or 72 h, this does not exclude the possibility that cytochrome c was involved at other times. The accelerated loss of neurons following gp120 compared to Tat exposure (see Figure 4) prompts speculation that gp120 might similarly hasten proapoptotic signaling events and induce cytochrome c release prior to 4 h; this notion warrants further investigation.
We additionally investigated the role of endonuclease G (endo G), a mitochondrion-specific nuclease that translocates into the nucleus during apop- tosis (Parrish et al, 2001; Li et al, 2001) . To test whether endo G is released following HIV-1 protein neurotoxicity, we exposed neuronal cultures to Tat 1−72 (100 nM) or gp120 (500 pM) for 4 h and 72 h ( Figure 7A-C) . Tat 1−72 , but not gp120, significantly increased the translocation of endo G from mitochondria into the cytoplasm at 4 h following exposure ( * P < .05 versus medium-treated control cultures).
The results suggested that Tat can induce apoptosis by activating endo G in addition to caspase activation, whereas gp120 failed to activate the endo G apoptotic pathway. This difference may explain why Z-DEVD-FMK was able to significantly attenuate gp120 neurotoxicity but unable to allay Tat 1−72 toxicity in the present study.
Discussion
The work presented here indicates that HIV-1 Tat 1−72 and gp120 are toxic to striatal neurons, and suggests they trigger neurodegeneration by activating caspase-3 and/or endo G apoptotic pathways. Although the mechanisms underlying HIV-induced cell death in the nervous system are not fully understood, results presented herein suggest that underlying neurotoxic pathways are highly complex and likely to differ for each viral protein. HIV-1 viral products can be released by infected cells (Ensoli et al, 1990; Munis et al, 1992; Robert-Guroff et al, 1990; Chang et al, 1997; Shutt and Soll, 1999 ; Jones
Figure 7
Effects of Tat and gp120 on endonuclease G (endo G) in the cytoplasm at 4 and 72 h following continuous treatment. HIV-1 Tat 1−72 (100 nM) increased cytoplasmic levels of in striatal neurons at 4 h in vitro ( * P < .05 versus vehicle-treated control cultures), whereas gp120 (500 pM) failed to increase endo G levels in the cytoplasm (Cyto) at 4 h or 72 h. Although cytoplasmic changes in endo G are shown (B, C), mitochondrial (Mito) levels were also assessed and varied inversely to cytoplasmic levels in control and Tat-treated neurons as expected (A). The results show the mean ± SEM of n = 4 experiments. IN Singh et al et al, 1998 , and can also induce the production and release of proinflammatory cytokines and cellular toxins in neural cells (Yeung et al, 1995; Adamson et al, 1996; Bagetta et al, 1996a; Kaul and Lipton, 1999; Nath et al, 1999) . Numerous lines of evidence suggest that extracellular proinflammatory cytokines and cellular toxins can induce neuronal apoptosis (Gabuzda et al, 1986; Gendelman et al, 1994; Shi et al, 1998; New et al, 1998; Bagetta et al, 1999; Holden et al, 1999; Zheng et al, 1999; Park et al, 2001; Takahashi et al, 1996) . Furthermore, several studies suggest that HIV-1 Tat and gp120 interact with neuronally expressed receptors to activate multiple proapoptotic signaling cascades in neurons Moore et al, 1997; New et al, 1997; Shi et al, 1998; Piller et al, 1999; Bonavia et al, 2001; Corasaniti et al, 2001; Haughey et al, 2001 ).
The present study shows that both Tat 1−72 and gp120 activated the apoptotic effector caspase-3. This is consistent with reports that HIV proteins, including Tat, Vpr, gp41, and Nef, can initiate apoptotic cascades in other neural cell types (Adamson et al, 1996; Yang et al, 1997; Kruman et al, 1998; Liu et al, 2000; Trillo-Pazos et al, 2000; Parrish et al, 2001; Li et al, 2001 ). The protective role of caspase inhibitors in experimental models of HIVE supports the involvement of caspases in the pathogenesis of neuro acquired immunodeficiency syndrome (neuroAIDS) (Garden et al, 2002) . The pan-caspase inhibitor Z-DEVD-FMK (Z-VAD-FMK) is an important tool to assess the role of caspases in cell death, whereas the substrate used to detect activity (Ac-DEVD-AMC) is selective for caspase-3 (Lin et al, 1999) . Interestingly, although both Tat 1−72 and gp120 caused increases in caspase-3 activity followed by neuronal cell death, only gp120 neurotoxicity was significantly blocked by caspase inhibition, suggesting that Tat 1−72 can induce neuronal death independent of caspase activation.
The release of cytochrome c from mitochondria into the cytosol can be a key event in the apoptotic process (Springer et al, 1999) . Our results indicate that exposure of mouse striatal neurons with Tat alone significantly increased cytochrome c levels in the cytoplasm following 4 h or 72 h exposure, whereas gp120 failed to induce significant increases in cytochrome c in the cytoplasm.
Endo G is primarily synthesized in a propeptide form in mammalian cells and its import into mitochondria is mediated by an amino-terminal mitochondrion-targeting sequence (Ruiz-Carillo and Renaud, 1987; Cote and Ruiz-Carillo, 1993) . Upon entry into the mitochondria, the signal peptide is cleaved-off and the mature endo G can be released from mitochondria following an appropriate apoptotic signal . We report here that exposure of mouse striatal neurons with HIV-1 Tat 1−72 significantly increased the translocation of endo G from mitochondria into the cytoplasm and this may be sufficient to induce death despite the presence of caspase inhibition. Thus, endo G levels in brains of HIV-infected patients may be an indirect indicator of the presence of Tat. In contrast, gp120 did not induce endo G translocation from mitochondria at 4 h or 72 h, suggesting an alternative apoptotic pathway different from Tat. Studies in progress are more directly addressing the role of endo G in Tat neurotoxicity.
Collectively, these findings suggest the involvement of at least two independent pathways, which execute neuronal apoptosis in neuroAIDS. The existence of multiple apoptotic pathways may underlie fundamental differences in Tat-versus gp120-mediated neurotoxicity in the striatum. Understanding the differences in HIV protein-mediated neurotoxicity is critical to the development of new therapeutic approaches for HIV dementia.
Materials and methods

Materials
Dulbecco's modified Eagle's medium (DMEM:F-12), B27, and antibiotic/antimycotic (penicillin/ streptomycin/amphoterin) were purchased from Gibco/Life Technologies (Grand Island, NY, USA). Purified mouse anti-cytochrome c monoclonal antibody was obtained from BD PharMingen, USA. Insulin, linoleic acid, and protein G beads were purchased from Sigma-Aldrich (St. Louis, MO, USA). Caspase-3 substrates, including Ac-AspGlu-Val-Asp-7-amino-4methylcoumarin (Ac-DEVD-AMC) and a reversible aldehyde inhibitor, Ac-DEVD-CHO (Ac-Asp-Glu-Val-Asp-aldehyde), were obtained either from Bachem Bioscience (King of Prussia, PA, USA) or from Molecular Probes (Eugene, OR, USA). A cell-permeable pan-caspase inhibitor II (Z-DEVD-FMK) was purchased from CalbiochemNovabiochem (San Diego, CA, USA) and used at 30 or 50 μM concentrations. The BCA protein assay kit and reagents were purchased from Pierce (Rockford, IL, USA). Bio-Rad Ready gels (10% and 12%) and Kaleidoscope prestained standards were obtained from Bio-Rad Laboratories (Hercules, CA, USA). An enhanced chemiluminescence (ECL) Western blot analysis system containing peroxidase-labeled antimouse or anti-rabbit antibodies was purchased from Amersham Pharmacia Biotech (Buckinghamshire, England). Timed, pregnant ICR mice were obtained from Charles River (Charles River, MA, USA).
Viral proteins
The tat gene encoding amino acids 1 to 72 was amplified from HIV BRU obtained from Dr. Richard Gaynor through the AIDS repository at the National Institutes of Health (NIH) and inserted into an Escherichia coli (PinPoint Xa-2) vector (Promega). Recombinant Tat 1−72 was prepared as described previously with minor modifications (Gurwell et al, 2001 ). Recombinant gp120 from HIV-SF2 made in Chinese hamster ovarian (CHO) cells was a gift from Chiron (Emeryville, CA, USA), and purified and handled as previously described (Holden et al, 1999; Haughey and Mattson, 2002) .
Striatal neuronal cultures
Striatal neuronal cultures from embryonic day 15 (E15) ICR mice were prepared as described before . Striata were dissected from ICR pups, dissociated, and striatal neurons were grown for 5 to 7 days in vitro (DIV) in serum-free DMEM/F-12 medium supplemented with 2% B-27, 1 μg/ml linoleic acid, 25 μg/ml insulin, and 1% antibiotic/antimycotic. Striatal neurons were seeded at identical densities (4 × 10 5 cells/cm 2 ) and grown on poly-D-lysine (0.1 mg/ml)-coated Costar 24-well plates in an incubator maintained at 35
• C to 36
• C in 5% CO 2 /95% air and high humidity. The cultures described in the present study are enriched in medium spiny neurons, which comprise about 85% to 95% of neurons in the mouse striatum, and contain about 3% to 8% astroglia and about 0.4% monocytes/microglia (Hauser, unpublished) , but which differ from an alternative mixed neuronal-glial striatal culture system previously characterized by us (Gurwell et al, 2001) .
Neuronal viability
To assess neuronal losses following continuous Tat 1−72 (100 nM) or gp120 (500 pM) exposure, timelapse, repeated-measures analyses of digital photomicrographs of individual neurons were performed as previously reported (Hauser et al, 1999; Goody et al, 2003) . Briefly, neuronal viability was assessed by repeatedly photographing the same neurons at 24-h intervals. Glass coverslips were lightly scored with a diamond marker, before placing into 12-well plates, to aid in finding the same field of neurons (neurons were plated on the opposite side from the score). This method of sampling is systematic, but arbitrary, because all neurons within a region predetermined before the onset of the experiment are assessed. The procedure also selects against background cell death that occurs in many primary neural culture systems, because the small proportion of dying cells are identified before the onset of treatment and are excluded from further study a priori without introducing experimenter bias. Neurons were photographed digitally using a Spot 2 camera (Diagnostic Instruments, Sterling Heights, MI) and Nikon Diaphot inverted microscope with phase-contrast optics and a 20× objective. About 50 to 75 neurons were arbitrarily sampled per culture. At least four to six cultures, each consisting of cells isolated and maintained from separate mice, were assessed per experimental group. Dying neurons were identified by the fragmentation and destruction of the cell body and neurites, as well as the loss of nuclear structure and/or shrinkage (pyknosis) ( Figure 4) ; detailed criteria for neuronal losses have been previously described (Hauser et al, 1999; Goody et al, 2003) .
The neuronal identity of the dying cells was further confirmed by exposing cells to 0.5 μg/ml EMA in Dulbecco's phosphate-buffered saline (PBS) for 30 min, permanently binding the EMA to the dying cells through photoaffinity labeling, and codetecting EMA-positive cells with neuron-specific antigenic markers as previously described (Gurwell et al, 2001) . Briefly, EMA is excluded from living cells, but intercalates to the DNA of dying cells, where it can be permanently linked via photoaffinity by exposure to a 45-W fluorescent light (15-cm distance) for 30 min at room temperature. Cells were then fixed with Zamboni's fixative containing 3% paraformaldehyde. Cell cultures were characterized by immunoreactivity to the neuronal markers, i.e., neuronal nuclear protein (NeuN) (mouse monoclonal anti-NeuN immunoglobulin G [IgG] , Chemicon, Temecula, CA, USA; at 1:500 dilution) and PGP 9.5 (rabbit polyclonal anti-PGP 9.5 IgG, Chemicon; 1:1800 dilution).
Caspase-3 activity
Caspase-3 activity was measured as previously described (Rigamonti et al, 2000) . Briefly, embryonic mouse striatal neurons grown for 5 to 7 days in vitro in serum-free DMEM/F12 medium were treated with vehicle-treated medium alone, Tat 1−72 (100 nM), or gp120 (500 pM). Cells were harvested at 4 h, 24 h, or 72 h after the treatments in ice-cold harvesting buffer (25 mM HEPES, pH 7.5, 5 mM EDTA, 1 mM EGTA, 5 mM magnesium chloride, 10 mM sucrose, 5 mM dithiothreitol, 1% 3-[-(3-chloramidopropyl)dimethylammonio]-1-propanesulfonic acid [CHAPS] , 10 μg/ml pepstatin, 10 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride [PMSF] ). After freezing and thawing three times, the cell lysates were centrifuged for 10 min at 5000 rpm, and the supernatants were centrifuged at 10, 000 × g for 60 min. The cell lysates thus obtained were stored at −80
• C. Lysates were incubated at 37
• C in a buffer containing 25 mM HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS, and 1 mM dithiothreitol supplemented with 50 μM Ac-DEVD-7-amino-4-methylcoumarin (AMC) in 96-well Costar plates. As a negative control, DEVD-CHO, a caspase-3-specific inhibitor, was added to the cell lysates 30 min before incubation with caspase-3 substrate, Ac-DEVD-AMC. The increase in fluorescence after the cleavage of the fluorogenic AMC moiety was monitored in a Cytofluor 4000 fluorimeter (Perspective Biosystems, Framingham, MA, USA) using 360-nm excitation and 460-nm emission wavelengths. Caspase-3 activity was expressed as fluorescence units per milligram of total cytosolic protein.
Immunoprecipitation, immunoblot analysis, and cytochrome c detection Release of cytochrome c from mitochondria was measured as previously described (Yang et al, 1997) . After incubation with vehicle-treated medium alone, 100 nM Tat 1−72 , or 500 pM gp120, striatal neurons were harvested with ice-cold buffer A containing 20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM PMSF, and 250 mM sucrose. Cell homogenates were centrifuged first at 750 × g for 10 min at 4
• C, and the resulting supernatant was centrifuged at 12, 000 × g for 30 min at 4
• C. The supernatant (cytosolic) fraction and the mitochondrial pellet fraction were used for the detection of cytochrome c. Equal amounts of cytosolic and mitochondrial protein from control and treated cultures were immunoprecipitated with 1 μg of purified mouse anti-cytochrome c monoclonal antibody (clone.6H2.B4 mouse IgG from BD PharMingen) for 3 h at 4
• C with constant rocking. Ten microliters of a 50% slurry of protein G-agarose beads in PBS was added, and the tubes were incubated overnight at 4
• C. The beads were pelleted, washed three times with PBS-1% Triton X-100, and suspended in 30 μl of Laemmli sample buffer (Laemmli, 1970) . After boiling for 5 min and centrifuging briefly, equal amounts of immunoprecipitated proteins (20 μg protein/lane) in the supernatant were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 12% polyacrylamide gels under reducing conditions (4% ß-mercaptoethanol). The proteins were electrophoretically transferred to a polyvinylidenedifluoride (PVDF) membrane. After blocking in TTBS buffer (10 mM Tris/HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) containing 5% skimmed milk powder, the membranes were incubated with primary monoclonal antibodies against cytochrome c (7H8.2C12 mouse IgG, PharMingen, 1:333 dilution) at room temp for 3 h. Finally, proteins were incubated 1 h at room temperature with a peroxidase-conjugated goat anti-mouse antibody. The blots were developed on Hyperfilm ECL film using Amersham ECL reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to manufacturers' instructions and detected using a phosphoimager (Molecular Dynamics Storm; Amersham Biosciences) or cooled CCD camera (Kodak Image Station 440 CF; Rochester, NY, USA). The optical density of the band in each lane was expressed relative to the vehicle-treated control in the same blot.
Protein determination
Protein concentrations were determined by the BCA method using a commercially available kit (Pierce; Rockford, IL, USA).
Statistics
Data were reported as the mean ± SEM of the average values from replicate samples obtained from at least n = 4 separate experiments. Significant overall differences among experimental groups were assessed using analysis of variance (ANOVA) (Statistica; StatSoft, Tulsa, OK, USA). If statistically significant differences were noted using ANOVA (P < .05), multiple group differences were compared post hoc using Duncan's test. Paired group differences were assessed using Student's t test. Homogeneity of variances was screened for all data using Levene's test.
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